|
Adult Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Expression pattern and prognostic significance of myosin light chain 9 (MYL9): a novel biomarker in glioblastoma.
|
31270134 |
2019 |
|
Adult Solid Neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
MYL9 protein in 136 primary ESCC tissues and other types of solid tumor was detected using immunohistochemistry.
|
28388691 |
2017 |
|
Apraxia, Developmental Verbal
|
0.010 |
Biomarker
|
disease |
BEFREE |
After inhibiting MLCK activity by using its specific inhibitor ML-7, the ER stress activator Tm failed to activate the MLCK/MLC2 pathway and could neither trigger CAS in mice nor induce VSMCs contraction in vitro.
|
29378169 |
2018 |
|
Brain Edema
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Inhibition of the myosin light chain kinase prevents hypoxia-induced blood-brain barrier disruption.
|
17419808 |
2007 |
|
Carcinoma of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Second, using the total RNA and protein extracted from lung cancer tissues (n = 240), adjacent non-cancer tissues (n = 240), and normal lung tissues (n = 300), we examined the MYLK and MYL9 expression levels by quantitative real-time PCR and Western blot.
|
25179839 |
2014 |
|
Cardiomyopathies
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Pseudo-phosphorylation of cardiac myosin regulatory light chain (RLC) has never been examined as a rescue method to alleviate a cardiomyopathy phenotype brought about by a disease causing mutation in the myosin RLC.
|
24374283 |
2014 |
|
Cardiomyopathy, Hypertrophic, Familial
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
This study focuses on the aspartic acid to valine substitution (D166V) in the myosin RLC shown to be associated with a malignant phenotype of familial hypertrophic cardiomyopathy (FHC).
|
24374283 |
2014 |
|
Cardiomyopathy, Hypertrophic, Familial
|
0.030 |
PosttranslationalModification
|
disease |
BEFREE |
Our data suggest that myosin RLC phosphorylation may have important translational implications for the treatment of RLC mutations-induced HCM and possibly play a role in other disease settings accompanied by depressed Ser15-RLC phosphorylation.
|
31101927 |
2019 |
|
Cardiomyopathy, Hypertrophic, Familial
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
The E22K mutation of myosin RLC that causes familial hypertrophic cardiomyopathy increases calcium sensitivity of force and ATPase in transgenic mice.
|
16076902 |
2005 |
|
Cerebral Edema
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Inhibition of the myosin light chain kinase prevents hypoxia-induced blood-brain barrier disruption.
|
17419808 |
2007 |
|
Childhood Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Expression pattern and prognostic significance of myosin light chain 9 (MYL9): a novel biomarker in glioblastoma.
|
31270134 |
2019 |
|
Childhood Osteosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this report, we show that when human osteosarcoma derived clonal cells (TE 85 clone F-5) (HOS), which are immortalized and nontumorigenic, undergo transformation following infection by Kirsten murine sarcoma virus (K-HOS) or by a chemical carcinogen [N-methyl-N-nitro-N-nitrosoguanidine (MNNG-HOS)], the smooth muscle MLC-2 mRNA is repressed.
|
1599878 |
1992 |
|
Childhood Solid Neoplasm
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
MYL9 protein in 136 primary ESCC tissues and other types of solid tumor was detected using immunohistochemistry.
|
28388691 |
2017 |
|
Colon Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
MBNL1-AS1 and MYL9 were poorly expressed in colon cancer.
|
31255531 |
2020 |
|
Colon Carcinoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
As an example, IG-SVM achieved a classification accuracy of 90.32% for colon cancer, which is difficult to be accurately classified, only based on three genes including CSRP1, MYL9, and GUCA2B.
|
29246519 |
2017 |
|
Colon Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Colon cancer cell-derived 12(S)-HETE induces the retraction of cancer-associated fibroblast via MLC2, RHO/ROCK and Ca<sup>2+</sup> signalling.
|
28013338 |
2017 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The significance for pVHL function of two further genes upregulated by wild-type pVHL was initially unclear, but re-expression of GNG4 (G protein gamma-4 subunit/guanine nucleotide-binding protein-4) and MLC2 (myosin light chain) in a RCC cell line suppressed tumour cell growth. pVHL regulation of CDKN1C, SPARC and GNG4 was not mimicked by hypoxia, whereas for six of 11 novel targets analysed (including DOC-2/DAB2 and MLC2) the effects of pVHL inactivation and hypoxia were similar.
|
15824735 |
2005 |
|
Cytotoxic Brain Edema
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Inhibition of the myosin light chain kinase prevents hypoxia-induced blood-brain barrier disruption.
|
17419808 |
2007 |
|
Cytotoxic Cerebral Edema
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Inhibition of the myosin light chain kinase prevents hypoxia-induced blood-brain barrier disruption.
|
17419808 |
2007 |
|
Endometriosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Three proteins, collapsin response mediator protein 2 (CRMP2), ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCH-L1) and myosin regulatory light polypeptide 9 (MYL9), were simultaneously identified from the two sets of samples from females with or without endometriosis by two-dimensional electrophoresis (2-DE).
|
23670619 |
2013 |
|
Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, we aimed to study the expression pattern and clinical significance of MYL9 in GBM.
|
31270134 |
2019 |
|
Glioblastoma Multiforme
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, we aimed to study the expression pattern and clinical significance of MYL9 in GBM.
|
31270134 |
2019 |
|
Glomerulonephritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In the kidney and immune organs, only Ifi202 expression increased with the development of GN in B6.MRLc1(82-100), and significant differences from C57BL/6 were observed even before disease onset.
|
20167632 |
2010 |
|
Head and Neck Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Automatic replanning was performed for 16 PC cases, initially planned for MLC1 (4 mm MLC) and reoptimized for MLC2 (5 mm) and MLC3 (10 mm) and for 19 HNC cases, replanned from MLC2 to MLC3.
|
29846751 |
2018 |
|
Hyperlipoproteinemia Type IIa
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
This study focuses on the aspartic acid to valine substitution (D166V) in the myosin RLC shown to be associated with a malignant phenotype of familial hypertrophic cardiomyopathy (FHC).
|
24374283 |
2014 |